MorphoSys has started dosing patients with B-cell acute lymphoblastic leukemia in a midstage trial of MOR208, a monoclonal Fc optimized anti-CD19 antibody. The study will include 30 patients.
Published in Brief:
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||